Académique Documents
Professionnel Documents
Culture Documents
Adapted from Paley,P, Screening for the major malignancies affecting women: Current guidelines. Am J Obstet Gynecol 2001;184:
Inflammatory
Tubo-ovarian abscess Tubo Benign tumors/cysts* Endometriotic cyst Brenner tumor Benign teratoma (dermoid cyst) Fibroma *Rare or very rare potential for malignancy
The challenge
Natural history of ovarian cancer not well understood
No well-defined precursor lesion well Length of time from localized tumor to dissemination is unknown
Multiple efforts underway to develop effective screening method for early detection
Risk factors
The majority of women with ovarian cancer have no known risk factors Most significant risk factor is genetic predisposition
Reproductive history
early menarche, nulliparity or age >30 at first child-bearing, and childlate menopause
Talcum powder
Some studies have shown slightly increased risk in women who use talc powder on genital area
American Cancer Society, 2001
Fertility drugs
prolonged use of Clomid, especially without achieving pregnancy
Protective factors
Multiparity: First pregnancy before age 30 Oral contraceptives: 5 years of use cuts risk nearly in half Tubal ligation Hysterectomy Lactation Bilateral oopherectomy
Delays in Diagnosis
Lack of severity and specificity of early symptoms
Early signs/symptoms may include bloating, gas, indigestion, abdominal fullness or discomfort, constipation, pelvic pressure, urinary frequency, abnormal vaginal bleeding, fatigue, back pain, leg pain
Diagnostic tools
History Pelvic Exam (including rectal) Transvaginal Ultrasound detection of masses and mass characteristics Tumor markers CA-125, LPA (plasma CAlysophosphatidic acid) CT assess spread to LN, pelvic and abdominal structures MRI best for distinguishing malignant from benign tumors
Diagnostic approach
If premenopausal and asymptomatic, with unilateral, mobile, simple cystic mass <8<810cm and no family history, can observe for 4-6 weeks and then repeat TVUS and pelvic exam.
If resolved, no further work-up necessary work If larger or unchanged, or if character of mass has changed on TVUS, surgical evaluation required
Diagnostic Approach
If postmenopausal and asymptomatic, with unilateral simple cyst <5cm AND normal CACA-125, can follow closely with repeat TVUS All other postmenopausal women with ovarian mass require surgical evaluation
Surgical Evaluation
Refer to Gyn-Onc specialist Gyn Exploratory laparotomy has been the gold standard and includes:
Peritoneal washings for cytology Evaluation of frozen section Complete staging procedure if borderline or malignant tumor on frozen section
Surgical Evaluation
Laparoscopy can be considered in premenopausal woman with ovarian mass small enough to remove via laparoscopic approach; not recommended if high suspicion for malignancy
Stage IV
Treatment
Depends on staging, tumor type, age, desire for future fertility Can include surgery, chemotherapy and/or radiation therapy Clinical trials are ongoing
Surgical treatment
Primary debulking and cytoreduction; may include:
Bilateral salpingo-oopherectomy salpingo Hysterectomy Lymphadenectomy (para-aortic, inguinal) (para Omentectomy brushing of diaphragm, examination of liver
Screening Strategies
Ultrasound (transvaginal vs transabdominal) Color-flow doppler ColorCA-125 CAOther tumor markers
Ultrasound
Both tranabdominal and transvaginal techniques identify enlarged ovaries or abnormal morphology; TVUS has better resolution One large study of TVUS underway has reported sensivity of 81% and specificity of 98.9% Major limitations are poor PPV in asymptomatic women and inability to detect malignances when ovaries are normal size Allows earlier stage detection
ColorColor-flow Doppler
Used in conjunction with TVUS Measures resistance in blood vessels supplying the ovaries May provide additional information to help distinguish malignant from benign masses
CACA-125
Sustained elevation in 82% of women with advanced ovarian cancer, but fewer than 1% of healthy women Poor sensitivity (elevated in only 50% of women with Stage I disease) Poor specificity (elevated in many gynecologic and non-gynecologic nonmalignancies as well as benign conditions)
CACA-125
Malignant conditions Cervical CA Fallopian tube CA Endometrial CA Pancreatic CA Colon CA Breast CA Lymphoma Mesothelioma
Benign conditions Endometriosis/Menses Uterine fibroids PID Pregnancy Diverticulitis Pancreatitis Liver disease Renal failure Appendicitis IBD
ACP
counsel high risk women about potential harms and benefits of screening
Screening, contd
American Cancer Society, AAFP and ACOG do not recommend screening for ovarian cancer in the general population Canadian Task Force on Periodic Health Examination
insufficient evidence to recommend for or against screening in high-risk women high-
References
1. 2. 3. American Cancer Society. Guidelines for the cancer-related cancercheckup: and update. Atlanta: American Cancer Society, 1993. Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998;25(3):255-264 1998;25(3):255DePriest PD, Gallion HH, van Nagell JR Jr et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65(3):408-414 1997;65(3):408Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Huntingt) 2000;14(11):16012000;14(11):1601-1607 Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19(1):3-10 2000;19(1):3Jacobs IJ, Skates SJ, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353(9160):1207-1210 1999;353(9160):1207-
4.
5. 6.
References, contd
7. Kurtz AB, Tsimikas JV, et al. Diagnosis and Staging of Ovarian Cancer: Comparative Values of Doppler and Conventional US, CT and MR Imaging Correlated with Surgery and Histopathologic AnalysisAnalysis-Report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27 1999;212(1):19NIH Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol follow1994;55(3 Pt2):S4-14. Pt2):S4Paley P. Screening for the major malignancies affecting women: Current guidelines. Am J Obstet Gynecol 2001;184:1021-1030. 2001;184:1021Rollins G. Developments in Cervical and Ovarian Cancer Screening: Implications for Current Practice. Ann Int Med 2000;133: 1021-1024 1021-
8.
9. 10.
References, contd
11. 12. Ryan: Kistners Gynecology & Womens Health, 7th ed. Mosby, Inc., 1999. Tierney LM, McPhee SJ, Papadakis MA, editors. Current Medical Diagnosis and Treatment, 39th edition. Lange Medical Books/ McGrawMcGraw-Hill, 2000. Tingulstad S, Hagen B, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet preGynaecol 1996;103(8):826-831 1996;103(8):826U.S. Preventive Services Task Force, Guidelines from Guide to Clinical Preventive Services, (Second Edition) 1996. Zanotti K, Kennedy A. Screening for Gynecologic Cancer. Med Clin N Am 1999;83:
13.
14. 15.